Actively Recruiting
Recurrent Liver Cancer: Reconceptualization and Reevaluation
Led by Nanjing Medical University · Updated on 2024-12-12
300
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer. The study will focus on recurrent liver cancer patients and compare participants to primary liver cancer patients as controls. The primary purpose is to assess whether the elevated levels of this protein can be used to monitor the recurrence of liver cancer. The main questions it aims to answer are: Is the levels of the protein significantly elevated in recurrent liver cancer patients compared to primary liver cancer patients? Can the protein be used as a reliable biomarker for the early detection of liver cancer recurrence? Researchers will compare the protein levels in the following groups: 50 recurrent liver cancer patients (training set) with abnormally high levels of the protein. 250 recurrent liver cancer patients (validation set) to confirm the protein's elevation in a separate cohort. Participants will be required to: * Provide blood samples for protein analysis. * Undergo regular follow-up visits for monitoring and data collection. * Allow access to their medical records for relevant clinical information.
CONDITIONS
Official Title
Recurrent Liver Cancer: Reconceptualization and Reevaluation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with primary hepatocellular carcinoma or diagnosed with non-HCC
- Able to read, understand, and sign the informed consent form
- Agree to provide blood samples and have good clinical compliance
- Complete clinical basic information including unique traceability number, age, gender, imaging and/or pathological diagnosis results (for primary liver disease patients), or imaging confirming heteromorphic liver cancer (for non-HCC patients)
You will not qualify if you...
- Pregnant women
- Patients who have received organ transplantation
- Non-HCC patients diagnosed with other tumors
- Patients with primary hepatocellular carcinoma complicated by other tumors
- Patients judged by the researcher as not meeting the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000
Actively Recruiting
Research Team
Z
zhang yewei, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here